Across TCGA pan-cancer cohorts, UBE2L3 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of UBE2L3’s most consistent transcriptional readouts.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where UBE2L3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types UBE2L3 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.
HNSC, LIHC, and KIRC are the cancer types where UBE2L3 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in UBE2L3 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.